More physicians are
turning to ORTHOVISC®1
- The only Non-Avian viscosupplement with up
to 6 months of efficacy with just 3 injections2 - Has the highest concentration of hyaluronic
acid (HA) among available viscosupplements3
HA is an important component of synovial fluid.
High concentration and high molecular
weight ORTHOVISC® closely matches
healthy synovial fluid. It provides safe
and lasting pain relief with no
reports of pseudoseptic reactions4.
Managed Care and Reimbursement Support Services
Physician Locator
Help patients locate you. Sign up to be
listed in the physician locator now.
Patient Education Seminars
Learn more about patient
education seminars.
CLICK HERE >>
This site is published by DePuy Mitek, Inc., which is solely responsible for its contents.
It is intended for healthcare professionals in the U.S. and contains U.S. based product information only.
ORTHOVISC® is manufactured by and is a registered trademark of Anika Therapeutics, Inc. Distributed by DePuy Mitek, Inc.
© DePuy Mitek, Inc. 2005 - 2010
AN OFFICIAL HEALTH AND FITNESS PROVIDER
Important Safety Information
ORTHOVISC® is indicated in the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and to simple analgesics, e.g. acetaminophen. In clinical studies, the most commonly reported adverse events were arthralgia, back pain, and headache. Other side effects included local injection site adverse events.
ORTHOVISC® is contraindicated in patients with known hypersensitivity to hyaluronate formulations or known hypersensitivity (allergy) to gram positive bacterial proteins. ORTHOVISC® should not be injected in patients with infections or skin diseases in the area of the injection site or joint. Strict aseptic technique should be used. The effectiveness of more than 1 course has not been established.
References
- Data on file.
- Brandt KD, Block JA, Michalski JP, Moreland LW, Caldwell JR, Lavin PT. Efficacy and safety of intraarticular sodium hyaluronate in knee osteoarthritis. ORTHOVISC® Study Group. Clin Orthop Relat Res. 2001;385:130-143.
- Manufacturer's full prescribing information for ORTHOVISC®, Synvisc®, Hyalgan®, Supartz®, and Euflexxa™.
Synvisc® is a registered trademark of Genzyme Corporation.
Hyalgan® is a registered trademark of sanofi-synthelabo.
Supartz® is a registered trademark of Seikagaku Corporation.
Euflexxa™ is a trademark of Ferring Pharmaceuticals, Inc. - FDA Maude/MDR database search, October 2008.